

Christine M Lovly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4139369/publications.pdf>

Version: 2024-02-01

63
papers

6,894
citations

136740

32
h-index

128067

60
g-index

65
all docs

65
docs citations

65
times ranked

10641
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers. <i>Journal of Clinical Oncology</i> , 2012, 30, 863-870.	0.8	1,435
2	Mechanisms of receptor tyrosine kinase activation in cancer. <i>Molecular Cancer</i> , 2018, 17, 58.	7.9	580
3	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. <i>Nature Communications</i> , 2016, 7, 10582.	5.8	412
4	Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions. <i>Cancer Discovery</i> , 2014, 4, 889-895.	7.7	334
5	RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK ⁺ positive lung cancer. <i>Nature Medicine</i> , 2015, 21, 1038-1047.	15.2	245
6	Rationale for co-targeting IGF-1R and ALK in ALK fusion ⁺ positive lung cancer. <i>Nature Medicine</i> , 2014, 20, 1027-1034.	15.2	243
7	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. <i>Nature Communications</i> , 2014, 5, 3518.	5.8	239
8	Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine. <i>Clinical Cancer Research</i> , 2015, 21, 2227-2235.	3.2	236
9	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 4837-4847.	3.2	223
10	Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , 2011, 71, 4920-4931.	0.4	203
11	Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials. <i>PLoS ONE</i> , 2012, 7, e35309.	1.1	173
12	Quantifying Drug Combination Synergy along Potency and Efficacy Axes. <i>Cell Systems</i> , 2019, 8, 97-108.e16.	2.9	142
13	Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. <i>Clinical Cancer Research</i> , 2018, 24, 2771-2779.	3.2	141
14	Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade. <i>Clinical Cancer Research</i> , 2015, 21, 4270-4277.	3.2	138
15	Characteristics of Lung Cancers Harboring <i>NRAS</i> Mutations. <i>Clinical Cancer Research</i> , 2013, 19, 2584-2591.	3.2	134
16	Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK ⁺ Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1901-1911.	0.5	127
17	<i>MAP2K1</i> (<i>MEK1</i>) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. <i>Clinical Cancer Research</i> , 2015, 21, 1935-1943.	3.2	124
18	SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. <i>Cancer Research</i> , 2017, 77, 2990-3000.	0.4	106

#	ARTICLE	IF	CITATIONS
19	Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse. <i>Journal of Thoracic Oncology</i> , 2018, 13, 112-123.	0.5	104
20	<i>EGFR</i> Fusions as Novel Therapeutic Targets in Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 601-611.	7.7	97
21	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2022, 40, 1231-1258.	0.8	96
22	Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel. <i>Oncologist</i> , 2014, 19, 616-622.	1.9	94
23	<i>EGFR</i> Kinase Domain Duplication (<i>EGFR</i> -KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. <i>Cancer Discovery</i> , 2015, 5, 1155-1163.	7.7	94
24	Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance. <i>Science Translational Medicine</i> , 2012, 4, 120ps2.	5.8	91
25	Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. <i>Cancer Immunology Research</i> , 2015, 3, 464-469.	1.6	91
26	Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. <i>Modern Pathology</i> , 2015, 28, 732-739.	2.9	85
27	An Acquired <i>HER2</i> T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with <i>HER2</i> Mutant-Driven Breast Cancer. <i>Cancer Discovery</i> , 2017, 7, 575-585.	7.7	85
28	On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. <i>Clinical Cancer Research</i> , 2019, 25, 3341-3351.	3.2	80
29	ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. <i>Molecular Cancer Research</i> , 2018, 16, 1724-1736.	1.5	74
30	Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1970-1981.	0.5	52
31	COVID-19 and immune checkpoint inhibitors: initial considerations. , 2020, 8, e000933.		45
32	Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. <i>Lung Cancer</i> , 2017, 111, 61-64.	0.9	44
33	<i>YES1</i> amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E6030-E6038.	3.3	44
34	Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5131-5140.	3.2	40
35	Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting. <i>Nature Communications</i> , 2021, 12, 1382.	5.8	34
36	The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome. <i>Translational Oncology</i> , 2016, 9, 163-165.	1.7	32

#	ARTICLE	IF	CITATIONS
37	<scp>BRAF</scp> internal deletions and resistance to <scp>BRAF</scp>/<scp>MEK</scp> inhibitor therapy. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 432-436.	1.5	31
38	Tumor Heterogeneity and Therapeutic Resistance. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e585-e593.	1.8	30
39	Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases. <i>Journal of Thoracic Oncology</i> , 2019, 14, e45-e48.	0.5	30
40	Optimizing the Sequence of Anti-EGFRâ€‘Targeted Therapy in EGFR-Mutant Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 542-552.	1.9	28
41	Severity of illness scores at presentation predict ICU admission and mortality in COVID-19. <i>Journal of Emergency and Critical Care Medicine</i> , 2021, 5, 7-7.	0.7	19
42	Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1211-1223.	0.5	17
43	Combating Acquired Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e165-e173.	1.8	16
44	Managing Resistance to EGFR- and ALK-Targeted Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 607-618.	1.8	16
45	Shades of T790M: Intratumor Heterogeneity in <i>EGFR</i>-Mutant Lung Cancer. <i>Cancer Discovery</i> , 2015, 5, 694-696.	7.7	15
46	Established, emerging and elusive molecular targets in the treatment of lung cancer. <i>Journal of Pathology</i> , 2018, 244, 565-577.	2.1	15
47	Sequencing Therapy for Genetically Defined Subgroups of Nonâ€‘Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 726-739.	1.8	13
48	The Panâ€‘Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. <i>Oncologist</i> , 2020, 25, e39-e47.	1.9	13
49	Strategies for Overcoming EGFR Resistance in the Treatment of Advanced-Stage NSCLC. <i>Current Treatment Options in Oncology</i> , 2012, 13, 516-526.	1.3	12
50	Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1084-1086.	7.7	12
51	Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived. <i>Cancer Discovery</i> , 2018, 8, 797-799.	7.7	11
52	Vulnerability of drugâ€‘resistant EML4â€‘ALK rearranged lung cancer to transcriptional inhibition. <i>EMBO Molecular Medicine</i> , 2020, 12, e11099.	3.3	11
53	Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100024.	0.6	11
54	Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance. <i>Cancers</i> , 2020, 12, 675.	1.7	11

#	ARTICLE	IF	CITATIONS
55	My Cancer Genome: Evaluating an Educational Model to Introduce Patients and Caregivers to Precision Medicine Information. AMIA Summits on Translational Science Proceedings, 2016, 2016, 112-21.	0.4	11
56	Expanding Horizons for Treatment of Early-Stage Lung Cancer. New England Journal of Medicine, 2022, 386, 2050-2051.	13.9	11
57	A Call to Action: Dismantling Racial Injustices in Preclinical Research and Clinical Care of Black Patients Living with Small Cell Lung Cancer. Cancer Discovery, 2021, 11, 240-244.	7.7	10
58	Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in <i>ALK</i> -positive (<i>ALK</i> +) solid tumors in a histology-agnostic setting.. Journal of Clinical Oncology, 2021, 39, TPS3155-TPS3155.	0.8	9
59	Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform. JCO Oncology Practice, 2022, 18, e36-e46.	1.4	6
60	Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC. JTO Clinical and Research Reports, 2021, 2, 100110.	0.6	5
61	Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion. Journal of Thoracic Oncology, 2019, 14, e29-e30.	0.5	4
62	Beyond biomarker testing: Aligning the needs of oncologist and diagnostic companies to improve biomarker results reports for accurate clinical treatment selection.. Journal of Clinical Oncology, 2022, 40, e18611-e18611.	0.8	0
63	Characterization of avoidable hospital admissions in patients with lung cancer in the immunotherapy and targeted therapy era.. Journal of Clinical Oncology, 2022, 40, e21133-e21133.	0.8	0